title: [Acute and chronic heart failure in light of the new ESC guidelines].
abstract: In June 2012, the New Guidelines for the Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology were published. According to the EMPHASIS-HF trial, mineralocorticoid receptor antagonists are indicated in all stages of symptomatic chronic heart failure under treatment with β-blockers and ACE inhibitors. Based on the SHIFT trial, patients with class NYHA II-IV heart failure, an ejection fraction <35%, and sinus rhythm with a heart rate of >70/min despite pharmacological treatment including β-blockers at the maximum tolerated dose should be treated with ivabradin. The RAFT trial justified the extended indication for CRT systems. In acute heart failure, the RELAX-AHF trial showed promising results with serelaxin. This manuscript summarizes the innovations of the new guidelines and the underlying clinical trials.
authors.affiliation: Klinik für Innere Medizin III, Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland, janine.poess@uks.eu.
authors.forename: J
authors.initials: J
authors.lastname: Pöss
authors.forename: A
authors.initials: A
authors.lastname: Link
authors.forename: M
authors.initials: M
authors.lastname: Böhm
mesh_terms: D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D058406:Cardiac Resynchronization Therapy / Q000592:standards*; D002309:Cardiology / Q000592:standards*; D002908:Chronic Disease; D005060:Europe; D006333:Heart Failure / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D017410:Practice Guidelines as Topic
chemical_list: D000319:Adrenergic beta-Antagonists